Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future

Increasing use of long-acting insulin analogues across countries is welcomed, adding to the range of insulins available, which increasingly includes biosimilars. A number of activities are needed to enhance the use of long-acting insulin analogue biosimilars in Japan, Korea and Pakistan.